Skip to main content
. Author manuscript; available in PMC: 2022 Aug 31.
Published in final edited form as: Exp Eye Res. 2022 May 23;220:109125. doi: 10.1016/j.exer.2022.109125

Fig. 5. Blocking CGRP signaling inhibits corneal hemangiogenesis and lymphangiogenesis in vivo.

Fig. 5.

A single figure-eight intrastromal suture was placed on mouse cornea and CGRP8-37 (200 μg/ml) or PBS control was administered via subconjunctival injection three times/week for two weeks (n = 5). (A) Representative images of corneal neovascularization (CNV) with slit-lamp photography. (B) Representative images of corneal whole mount stained with CD31 (Blood vessels, green) and LYVE-1 (Lymph vessels, red), × 100 magnification, dashed line indicates the limbus. (C, D) Quantification of CNV area (CD31, C) and Lymph vessel area (LYVE-1, D) at day 14. (E) mRNA level of VEGF-A in cornea was assessed. *p < 0.05, **p < 0.01, unpaired t-test. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)